Find, compare & contact
Vadimezan
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Vadimezan API 117570-53-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Vadimezan. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Vadimezan
- Synonyms:
- (5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid , 5,6-Dimethyl-9-oxo-9H-xanthene-4-acetic acid , 5,6-Dimethylxanthenone-4-acetic acid , 5,6-Dimethylxanthenoneacetic acid , 5,6-MeXAA , Dimethyloxoxanthene acetic acid , DMXAA , Vadimézan , Vadimezanum
- Cas Number:
- 117570-53-3
- DrugBank number:
- DB06235
- Unique Ingredient Identifier:
- 0829J8133H
General Description:
Vadimezan is a chemical compound identified by the CAS number 117570-53-3. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Vadimezan functions by: ASA404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The proposed mechanism of action for ASA404 is directly increasing permeability of the tumor's endothelial cells. Vasoactive mediators such as tumor necrosis factor (TNF) may also be implicated. Increased permeability of tumor cell vasculature may allow increased permeation of anticancer treatments such as cytotoxic drugs, antibodies, drug conjugates and gene therapy. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Vadimezan belongs to the class of organic compounds known as xanthones. These are polycyclic aromatic compounds containing a xanthene moiety conjugated to a ketone group at carbon 9. Xanthene is a tricyclic compound made up of two benzene rings linearly fused to each other through a pyran ring, classified under the direct parent group Xanthones. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Benzopyrans class, specifically within the 1-benzopyrans subclass.
Categories:
Vadimezan is categorized under the following therapeutic classes: Antineoplastic Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, UGT1A9 Substrates, UGT2B7 substrates, Xanthenes. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Vadimezan is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
